Mustafa Kayali1, Melih Balci1, Yilmaz Aslan1, Ovunc Bilgin1, Ozer Guzel1, Altug Tuncel2, Ali Atan3. 1. Third Department of Urology, Ankara Numune Research and Training Hospital, Ministry of Health, Ankara, Turkey. 2. Third Department of Urology, Ankara Numune Research and Training Hospital, Ministry of Health, Ankara, Turkey. Electronic address: tuncelaltug@yahoo.com. 3. Department of Urology, Gazi University, School of Medicine, Ankara, Turkey.
Abstract
OBJECTIVE: To investigate the relationship between prostate cancer (PCa), presence of metabolic syndrome (MetS), and late-onset hypogonadism (LOH). MATERIALS AND METHODS: One hundred seventy patients who underwent transrectal ultrasonography-guided prostate needle biopsy were included in this study. For the diagnosis of MetS, American Heart Association/National Heart, Lung, and Blood Institute criteria were used. For the diagnosis of LOH, Androgen Deficiency in Aging Males questionnaire and serum total and free testosterone levels were used. Patients were divided into 4 groups according to the presence of MetS and LOH: group 1, MetS and LOH; group 2, with MetS but without LOH; group 3, with LOH but without MetS; and group 4, with neither MetS nor LOH. RESULTS: The mean age of the patients was 63.7 ± 7.2 years. In group 1, 12 patients (37.5%); in group 2, 5 patients (25%); in group 3, 11 patients (26.8%); and in group 4, 14 patients (18.2%) were diagnosed with PCa. Aggressive PCa was determined in 7 patients in group 1 (21.9%), 2 patients in group 2 (10%), 5 patients in group 3 (12.2%), and 5 patients in group 4 (6.5%). There was a statistically significant difference only in between groups 1 and 4 in terms of detection of PCa (37.5% vs 18.2%, P = .031) and aggressive PCa (21.9% vs 6.5%, P = .019). CONCLUSION: These results highlight the fact that coexistence of MetS and LOH increases the risk of PCa and aggressive PCa.
OBJECTIVE: To investigate the relationship between prostate cancer (PCa), presence of metabolic syndrome (MetS), and late-onset hypogonadism (LOH). MATERIALS AND METHODS: One hundred seventy patients who underwent transrectal ultrasonography-guided prostate needle biopsy were included in this study. For the diagnosis of MetS, American Heart Association/National Heart, Lung, and Blood Institute criteria were used. For the diagnosis of LOH, Androgen Deficiency in Aging Males questionnaire and serum total and free testosterone levels were used. Patients were divided into 4 groups according to the presence of MetS and LOH: group 1, MetS and LOH; group 2, with MetS but without LOH; group 3, with LOH but without MetS; and group 4, with neither MetS nor LOH. RESULTS: The mean age of the patients was 63.7 ± 7.2 years. In group 1, 12 patients (37.5%); in group 2, 5 patients (25%); in group 3, 11 patients (26.8%); and in group 4, 14 patients (18.2%) were diagnosed with PCa. Aggressive PCa was determined in 7 patients in group 1 (21.9%), 2 patients in group 2 (10%), 5 patients in group 3 (12.2%), and 5 patients in group 4 (6.5%). There was a statistically significant difference only in between groups 1 and 4 in terms of detection of PCa (37.5% vs 18.2%, P = .031) and aggressive PCa (21.9% vs 6.5%, P = .019). CONCLUSION: These results highlight the fact that coexistence of MetS and LOH increases the risk of PCa and aggressive PCa.
Authors: M Gacci; G I Russo; C De Nunzio; A Sebastianelli; M Salvi; L Vignozzi; A Tubaro; G Morgia; S Serni Journal: Prostate Cancer Prostatic Dis Date: 2017-02-21 Impact factor: 5.554
Authors: Cosimo De Nunzio; Giuseppe Simone; Aldo Brassetti; Riccardo Mastroianni; Devis Collura; Giovanni Muto; Michele Gallucci; Andrea Tubaro Journal: BMC Cancer Date: 2016-07-07 Impact factor: 4.430
Authors: Kyung Jae Hur; Kyu Won Lee; Su Jin Kim; Kang Sup Kim; Woong Jin Bae; Hyuck Jin Cho; Sung Hoo Hong; Ji Youl Lee; Tae Kon Hwang; Sae Woong Kim Journal: World J Mens Health Date: 2015-12-23 Impact factor: 5.400